Jefferies Group Downgrades Hikma Pharmaceuticals (LON:HIK) to Underperform

Hikma Pharmaceuticals (LON:HIK) was downgraded by investment analysts at Jefferies Group to an “underperform” rating in a research note issued to investors on Wednesday, January 10th. They presently have a GBX 895 ($12.14) price target on the stock, down from their previous price target of GBX 1,074 ($14.56). Jefferies Group’s target price suggests a potential downside of 10.77% from the company’s current price.

HIK has been the subject of several other reports. Stifel Nicolaus lowered their target price on shares of Hikma Pharmaceuticals from GBX 1,320 ($17.90) to GBX 1,000 ($13.56) and set a “hold” rating for the company in a research note on Thursday, November 9th. Numis Securities raised shares of Hikma Pharmaceuticals to a “buy” rating and set a GBX 1,300 ($17.63) price objective for the company in a research note on Thursday, November 9th. Peel Hunt reissued a “hold” rating and set a GBX 1,390 ($18.85) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, October 31st. JPMorgan Chase & Co. lowered their price objective on shares of Hikma Pharmaceuticals from GBX 1,500 ($20.34) to GBX 1,250 ($16.95) and set a “neutral” rating for the company in a research note on Friday, October 6th. Finally, Morgan Stanley reissued an “equal weight” rating and set a GBX 1,100 ($14.92) price objective on shares of Hikma Pharmaceuticals in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of GBX 1,171 ($15.88).

Shares of Hikma Pharmaceuticals (HIK) opened at GBX 1,003 ($13.60) on Wednesday. The company has a market cap of $2,400.00 and a P/E ratio of 2,006.00. Hikma Pharmaceuticals has a 12 month low of GBX 906.50 ($12.29) and a 12 month high of GBX 2,346 ($31.81).

ILLEGAL ACTIVITY WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/17/jefferies-group-lowers-hikma-pharmaceuticals-hik-to-underperform.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply